Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belrestotug and Nelistotug Regimens in Previously Treated NSCLC
NCT06926673Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2021
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of belrestotug, nelistotug in non-small cell lung cancer (NSCLC), sponsored by GSK. Started Dec 2021; status: completed.
02
Drugs
belrestotugnelistotug
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06926673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06926673.